Effect of 5‐α‐reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC‐3
- 1 May 1994
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 24 (5) , 229-236
- https://doi.org/10.1002/pros.2990240503
Abstract
The endocrine treatment of metastatic prostate cancer includes castration which reliably lowers the serum testosterone (T); however, the effect on intratumor levels of T and dihydrotestosterone (DHT) is less predictable. In vitro work demonstrated that the human prostate cancer cell line PC-3 had significant 5-a-reductase activity that could be inhibited with 17b-N, N-diethylcarbamoyl-4-aza-5a-androstan-3-one (4MA). In this study, we examined the effect of 5-a-reductase inhibition with 4MA and androgen suppression with dexamethasone on the growth characteristics and intratumor androgen levels in the PC-3 cell line in male athymic nude mice (Balb/c). The mice were randomized into six treatment groups: 1) noncastrate vehicle control, 2) 4MA, 0.25 mg/day, 3) 4MA, 1 mg/day, 4) dexamethasone, 25 μg/day, 5) 4MA, 1 mg/day, and dexamethasone, 25 μg/day, and 6) castrate control group. After 21 days of treatment the animals were sacrificed, serum collected, and tumors harvested. Each treatment produced intratumor DHT levels equivalent to the castrate group. Only the low dose 4MA caused a reduction in intratumor DHT without producing castrate levels of circulating T. The combination of dexamethasone and 4MA was less effective in lowering the intratumor DHT/T ratio than 4MA alone. No significant differences in tumor growth parameters were noted between intact control animals and any of the treatment arms. Serum T levels correlated poorly with intratumor androgen levels. Five-a-reductase inhibition produced castrate levels of intratumor DHT in the nonandrogen-dependent prostate cancer cell line PC-3. The combination of dexamethasone and 5-a-reductase inhibition with 4MA appears to be less effective in lowering intratumor androgen levels than either therapy alone.Keywords
This publication has 21 references indexed in Scilit:
- In vivo assay for conversion of testosterone to dihydrotestosterone by rat prostatic steroid 5α-reductase and comparison of two inhibitorsThe Prostate, 1991
- Prostate Long-Term Epithelial Cell Lines. Biological and Biochemical FeaturesAnnals of the New York Academy of Sciences, 1990
- Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in menThe Journal of Steroid Biochemistry and Molecular Biology, 1989
- Comparison of dihydrotestosterone levels in prostatic cancer metastases and primary prostate cancerThe Prostate, 1989
- Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostateThe Journal of Steroid Biochemistry and Molecular Biology, 1988
- Androgen levels in prostatic tissue of patients with carcinoma of the prostate treated with the combined therapy using an LHRH agonist and a pure antiandrogenEuropean Journal of Cancer and Clinical Oncology, 1986
- Prostatic effects induced in dogs by chronic or acute oral administration of 5α‐reductase inhibitorsThe Prostate, 1986
- Regulation and compartmentalization ofandrogens in rat prostate and muscleJournal of Steroid Biochemistry, 1983
- Content of 5α-reduced androgens in subcellular compartments of dog prostateJournal of Steroid Biochemistry, 1979
- STEROIDS OF ADRENAL ORIGIN METABOLIZED BY HUMAN PROSTATIC TISSUE BOTH IN VIVO AND IN VITROJournal of Endocrinology, 1974